Elevated levels of TOPK and TLR4 in high-grade breast cancer tissues further support their involvement in tumor progression, positioning TOPK as a promising therapeutic target for inflammation-driven cancer metastasis 78. This evidence concerns the gene PBK and breast carcinoma.